2025 Trends in Specialty Drug Benefits Report
More than 200 industry leaders have spoken: the 2025 Trends in Specialty Drug Benefits Report, co-sponsored by Genentech and Pharmaceutical Strategies Group (PSG), is here. This executive summary captures how payers are resetting specialty drug strategies and what that means for coverage, pricing and patient access. Most notably, 43% said managing overall specialty costs is the top priority, while 41% are focused on total cost of care.
What this means for health systems and plan-aligned leaders is practical and immediate—check out useful insights on contract approaches, utilization management and affordability programs.
Key learnings:
What this means for health systems and plan-aligned leaders is practical and immediate—check out useful insights on contract approaches, utilization management and affordability programs.
Key learnings:
- Evolving payer priorities, with a focus on managing the total cost of care and growing interest in alternative pricing arrangements
- Current usage trends of alternative funding programs (AFPs)
- The unintended consequences of utilization management
Please fill out the form to download the Executive Summary to see where payers are headed next and how to respond.